Heart & Lung: The Journal of Acute and Critical Care
Volume 34, Issue 5 , Pages 360-363 , September 2005

Extended spectrum β-lactamase–producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B

References 

  1. Saklayen MG . CAPD peritonitis (Incidence, pathogens, diagnosis, and management) . Med Clin North Am . 1990;74:997–1010
  2. Nachimuthu S , Visconti EB , Pannone JB , et al.   Bacteroides peritonitis associated with colon cancer in a continuous ambulatory peritoneal dialysis patient . South Med J . 2001;94:1021–1022
  3. Ma M . Antibiotic dosing in patients on peritoneal dialysis . Antibiot Clin . 1997;2:12–15
  4. Qadir MT , Cunha BA . Penicillium peritonitis in a patient receiving continuous ambulatory peritoneal dialysis . Heart Lung . 1998;27:67–68
  5. Berbari N , Johnson DH , Cunha BA . Xanthomonas maltophilia peritonitis in a patient undergoing peritoneal dialysis . Heart Lung . 1993;33:282–283
  6. Vas S , Oreopoulos DG . Infections in patients undergoing peritoneal dialysis . Infect Dis Clin North Am . 2001;15:743–774
  7. Kim B-N , Woo J-H , Kim M-N , et al.   Clinical implications of extended spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia . J Hosp Infect . 2001;52:99–106
  8. Piroth L , Aubé H , Doise J-M , et al.   Spread of extended-spectrum, β-lactamase-producing Klebsiella pneumoniae (are β-lactamase inhibitors of therapeutic value?) . Clin Infect Dis . 1998;27:76–80
  9. Shehabi AA , Mahafzah A , Baadran I , et al.   High incidence of Klebsiella pneumoniae clinical isolates to extended-spectrum β-lactam drugs in intensive care units . Diagn Microbiol Infect Dis . 2000;36:53–56
  10. Du B , Long Y , Liu H , et al.   Extended-spectrum beta-lactamase producing Escherichia coli Klebsiella pneumoniae bloodstream infection (risk factors and clinical outcome) . Intensive Care Med . 2001;28:1718–1723
  11. Quinn JP . Clinical significance of extended-spectrum beta-lactamases . Eur J Clin Microbiol Infect Dis . 1994;13(Suppl 1):39–42
  12. Wong-Beringer A . Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae . Pharmacotherapy . 2001;21:583–592
  13. In:  Koneman EW ,  Allen SD ,  Janda WM ,  Schreckenberger PC ,  Winn WC editor. Color atlas and textbook of diagnostic microbiology, ed 5 . New York: Lippincott; 1977;p. 11
  14. In:  Kucers A ,  Crowe SM ,  Grayson ML , et al. editor. The polymyxins. In (The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral drugs) . ed 5. Oxford: Butterworth Heinemann; 1997;p. 323–370
  15. Evans ME , Feola DJ , Rapp RP . Polymyxin B sulfate and colistin (old antibiotics for emerging multiresistant gram-negative bacteria) . Ann Pharmacother . 1999;33:960–967
  16. Tascini C , Ferranti S , Messina F , Menichetti F . In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against multiresistant Pseudomonas aeruginosa isolate . Clin Microbiol Infect . 2000;6:687–691
  17. Sarria JC , Angulo-Pernett F , Kimbrough RC , et al.   Use of intravenous polymyxin B during continuous venovenous hemodialysis . Eur J Clin Microbiol Infect Dis . 2004;23:340–341
  18. Linden PK , Kusne S , Coley K , et al.   Use of parenteral colistin for the treatment of serious infection to antimicrobial-resistant Pseudomonas aeruginosa . Clin Infect Dis . 2003;7:154–160
  19. Urban C , Tay E , Koprivnjak T , et al.   Polymyxin B-resistant Acinetobacter baumannii clinical isolate susceptible to recombinant BPI21 and Cecropin P1 . Antimicrob Agents Chemother . 2001;45:994–995
  20. Levin AS , Barone AA , Penco J , et al.   Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Clin Infect Dis . 1999;28:1008–1011

PII: S0147-9563(04)00213-4

doi: 10.1016/j.hrtlng.2004.11.001

Heart & Lung: The Journal of Acute and Critical Care
Volume 34, Issue 5 , Pages 360-363 , September 2005

Article Tools